The prognostic role of TP53 mutations in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy is undefined. In a large patient cohort study, those with TP53 mutations had worse progression-free and overall survival, and mutant TP53 was predictive of treatment outcome in patients with the germinal centre B-cell and activated B-cell subtypes; underscoring TP53 stratification potential in these patient subsets.
ORIGINAL RESEARCH PAPER
Xu-Monette, Z. Y. et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood doi:10.1182/blood-2012-05-433334
Rights and permissions
About this article
Cite this article
TP53 mutations prognostic for DLBCL treated with R-CHOP. Nat Rev Clin Oncol 9, 611 (2012). https://doi.org/10.1038/nrclinonc.2012.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.178
